American Journal of Ophthalmology
Volume 148, Issue 2 , Pages 192-198 , August 2009

Frontiers in the Management of Retinoblastoma

  • Phoebe Lin
    • ,
  • Joan M. O'Brien

      Affiliations

    • Corresponding Author InformationInquiries to Joan M. O'Brien, Koret Vision Research Center, 10 Koret Way, Room K-231, Box 0730, San Francisco, CA 94143

,Accepted 1 April 2009.

References 

  1. Abramson DH. Retinoblastoma incidence in the United States. Arch Ophthalmol. 1990;108:1514
  2. Devesa SS. The incidence of retinoblastoma. Am J Ophthalmol. 1975;80:263–265
  3. Leal-Leal C, Flores-Rojo M, Medina-Sanson A, et al. A multicentre report from the Mexican Retinoblastoma Group. Br J Ophthalmol. 2004;88:1074–1077
  4. Abramson DH. Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2005;46:2683–2691
  5. Albert DM. Historic review of retinoblastoma. Ophthalmology. 1987;94:654–662
  6. Dondey JC, Staffieri S, McKenzie J, Davie G, Elder J. Retinoblastoma in Victoria, 1976–2000: changing management trends and outcomes. Clin Experiment Ophthalmol. 2004;32:354–359
  7. Berman EL, Donaldson CE, Giblin M, Martin FJ. Outcomes in retinoblastoma, 1974–2005: the Children's Hospital, Westmead. Clin Experiment Ophthalmol. 2007;35:5–12
  8. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986;323:643–646
  9. Abramson DH, Schefler AC. Update on retinoblastoma. Retina. 2004;24:828–848
  10. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18:41–53viii
  11. Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276–2280
  12. Chantada G, Doz F, Antoneli CB, et al. A proposal for an International Retinoblastoma Staging System. Pediatr Blood Cancer. 2006;47:801–805
  13. Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Naduvilath TJ. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol. 2002;120:1653–1658
  14. Shields CL, Santos MC, Diniz W, et al. Thermotherapy for retinoblastoma. Arch Ophthalmol. 1999;117:885–893
  15. Zage PE, Reitman AJ, Seshadri R, et al. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma. Pediatr Blood Cancer. 2008;50:567–572
  16. Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after sub-Tenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003;121:1120–1124
  17. Kiratli H, Kocabeyoglu S, Bilgic S. Severe pseudo-preseptal cellulitis following sub-Tenon's carboplatin injection for intraocular retinoblastoma. J AAPOS. 2007;11:404–405
  18. Schmack I, Hubbard GB, Kang SJ, Aaberg TM, Grossniklaus HE. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol. 2006;142:310–315
  19. Shields JA, Shields CL, Meadows AT. Chemoreduction in the management of retinoblastoma. Am J Ophthalmol. 2005;140:505–506
  20. Chantada GL, Dunkel IJ, Antoneli CB, et al. Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma. Pediatr Blood Cancer. 2007;49:256–260
  21. Chantada GL, Doz F, Orjuela M, et al. World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer. 2008;50:692–694
  22. Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology. 1988;95:1583–1587
  23. Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst. 2008;100:1771–1779
  24. Dunkel IJ, Aledo A, Kernan NA, et al. Successful treatment of metastatic retinoblastoma. Cancer. 2000;89:2117–2121
  25. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of metastatic retinoblastoma. Ophthalmology. 2003;110:1237–1240
  26. Kremens B, Wieland R, Reinhard H, et al. High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant. 2003;31:281–284
  27. Valverde JR, Alonso J, Palacios I, Pestana A. RB1 gene mutation update, a meta-analysis based on 932 reported mutations available in a searchable database. BMC Genet. 2005;6:53
  28. Leiderman YI, Kiss S, Mukai S. Molecular genetics of RB1— the retinoblastoma gene. Semin Ophthalmol. 2007;22:247–254
  29. Lohmann DR, Gallie BL. Retinoblastoma: revisiting the model prototype of inherited cancer. Am J Med Genet C Semin Med Genet. 2004;129C:23–28
  30. Klutz M, Brockmann D, Lohmann DR. A parent-of-origin effect in two families with retinoblastoma is associated with a distinct splice mutation in the RB1 gene. Am J Hum Genet. 2002;71:174–179
  31. MacPherson D, Conkrite K, Tam M, Mukai S, Mu D, Jacks T. Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. Embo J. 2007;26:784–794
  32. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420:25–27
  33. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006;444:61–66
  34. Elison JR, Cobrinik D, Claros N, Abramson DH, Lee TC. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch Ophthalmol. 2006;124:1269–1275
  35. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 2003;63:3637–3645
  36. Dalgard CL, van Quill KR, O'Brien JM. Evaluation of the in vitro and in vivo anti-tumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res. 2008;14:3113–3123
  37. Tonelli R, Purgato S, Camerin C, et al. Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis. Mol Cancer Ther. 2005;4:779–786
  38. MacPherson D, Dyer MA. Retinoblastoma: from the two-hit hypothesis to targeted chemotherapy. Cancer Res. 2007;67:7547–7550
  39. Van Quill KR, Dioguardi PK, Tong CT, et al. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology. 2005;112:1151–1158
  40. Tsui JY, Dalgard C, van Quill KR, et al. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 2008;49:490–496
  41. Suzuki S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol. 2004;9:1–6
  42. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol. 2004;9:69–73
  43. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115:1398–1404

PII: S0002-9394(09)00268-2

doi: 10.1016/j.ajo.2009.04.004

American Journal of Ophthalmology
Volume 148, Issue 2 , Pages 192-198 , August 2009

Article Tools